Karl Naegler
Partner, Sofinnova Partners – Capital Strategy
Karl Naegler is a Partner in the Sofinnova Capital Strategy. He joined us in September 2024, bringing a strong track record of 20 years of investment experience.
Before joining Sofinnova, he was was a Managing Partner at Wellington Partners Life Sciences and before that, a Partner at Gimv. In those roles, he was instrumental in the success of several high-profile startups, from company formation to exit. These include Seamless Therapeutics, launched with a top syndicate of investors; Breath Therapeutics, a co-investment with Sofinnova, acquired by Zambon; Covagen, acquired by Johnson & Johnson, and Prosonix, acquired by Circassia Pharmaceuticals.
"Sofinnova is a world-class firm that truly leads life sciences venture capital in Europe. The opportunity to be part of an investment platform spanning multiple sectors, stages and geographies, with such a high-caliber team, was an opportunity I could not pass up. I look forward to bringing my experience to bear as we build and support the most innovative companies in life sciences across Europe."
His career also includes key roles at Ventech and Atlas Venture.Karl earned his Ph.D. in Molecular Neurobiology from the Max-Delbrück-Center for Molecular Medicine in Berlin followed by a position as Scientific Fellow at CNRS for Neurochemistry in Strasbourg.
